Trial Profile

SWitching InflixiMab to SUbcut from Intravenous Therapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary)
Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Focus Therapeutic Use
Acronyms SWIMSUIT

Most Recent Events

09 May 2023 Results assessing the clinical outcomes of patients switching from intravenous (IV) infliximab to SC CT-P13 presented at the Digestive Disease Week 2023
18 Jan 2022 Status changed from active, no longer recruiting to completed.
18 Jan 2022 Planned End Date changed from 31 Jan 2022 to 2 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com